-
Mark D McBriar, Henry Guzik,
Sherry Shapiro,
Ruo Xu,
Jaroslava Paruchova,
John W Clader,
Kim O'neill,
Brian Hawes,
Steve Sorota,
Michael Margulis,
Kristal Tucker,
Daniel J Weston,
Kathleen Cox
[show abstract]
[hide abstract]
ABSTRACT: Herein, we report the discovery of an effective strategy to modulate liabilities related to affinity of previously disclosed bicyclohexane MCHR-1 antagonists for the hERG channel. This paper describes one of several strategies incorporated to limit hERG binding via modifications of a terminal aryl group in an otherwise promising bicyclohexyl urea series.
Bioorganic & Medicinal Chemistry Letters 09/2006; 16(16):4262-5. · 2.55 Impact Factor
-
Ruo Xu,
Shengjian Li,
Jaroslava Paruchova,
Mark D McBriar, Henry Guzik,
Anandan Palani,
John W Clader,
Kathleen Cox,
William J Greenlee,
Brian E Hawes,
Timothy J Kowalski,
Kim O'Neill,
Brian D Spar,
Blair Weig,
Daniel J Weston
[show abstract]
[hide abstract]
ABSTRACT: Melanin concentrating hormone (MCH) receptor antagonists have been proposed as potential treatments of obesity. MCH receptor antagonists with a biphenylamine subunit have been reported previously at Schering-Plough. Herein, we report the discovery of bicyclo[4.1.0]heptanes as replacements for the middle phenyl ring of the biphenylamine moiety in order to eliminate its potential mutagenic liability. Structure-activity relationships in this series were found to be very similar to those of the original biphenylamine series, suggesting that the two series have similar binding modes.
Bioorganic & Medicinal Chemistry 06/2006; 14(10):3285-99. · 2.92 Impact Factor
-
Mark D McBriar, Henry Guzik,
Sherry Shapiro,
Jaroslava Paruchova,
Ruo Xu,
Anandan Palani,
John W Clader,
Kathleen Cox,
William J Greenlee,
Brian E Hawes,
Timothy J Kowalski,
Kim O'neill,
Brian D Spar,
Blair Weig,
Daniel J Weston,
Constance Farley,
John Cook
[show abstract]
[hide abstract]
ABSTRACT: Melanin-concentrating hormone (MCH) is a cyclic, nonadecapeptide expressed in the CNS of all vertebrates that regulates feeding behavior and energy homeostasis via interaction with the central melanocortin system. Regulation of this interaction results in modulation of food intake and body weight gain, demonstrating significant therapeutic potential for the treatment of obesity. The MCH-1 receptor (MCH-R1) has been identified as a key target in MCH regulation, as small molecule antagonists of MCH-R1 have demonstrated activity in vivo. Herein, we document our research in a bicyclo[3.1.0]hexyl urea series with particular emphasis on structure-activity relationships and optimization of receptor occupancy, measured both in vitro and via an ex vivo binding assay following an oral dosing regimen. Several compounds have been tested in vivo and exhibit oral efficacy in relevant acute rodent feeding models. In particular, 24u has proven efficacious in chronic rodent models of obesity, showing a statistically significant reduction in food intake and body weight over a 28 day study.
Journal of Medicinal Chemistry 05/2006; 49(7):2294-310. · 5.25 Impact Factor
-
Timothy J Kowalski,
Brian D Spar,
Blair Weig,
Constance Farley,
John Cook,
Lorraine Ghibaudi,
Steve Fried,
Kim O'Neill,
Robert A Del Vecchio,
Mark McBriar, Henry Guzik,
John Clader,
Brian E Hawes,
Joyce Hwa
[show abstract]
[hide abstract]
ABSTRACT: Melanin concentrating hormone (MCH) is a cyclic neuropeptide expressed in the lateral hypothalamus that plays an important role in energy homeostasis. To investigate the pharmacological consequences of inhibiting MCH signaling in murine obesity models, we examined the effect of acute and chronic administration of a selective MCH1 receptor antagonist (SCH-A) in diet-induced obese (DIO) and Lep(ob/ob) mice. Oral administration of SCH-A for 5 consecutive days (30 mg/kg q.d.) produced hypophagia, a loss of body weight and adiposity, and decreased plasma leptin levels in DIO mice, and hypophagia and reduced weight gain in Lep(ob/ob) mice. Chronic administration of SCH-A to DIO mice decreased food intake, body weight and adiposity, and plasma leptin and free fatty acids. These effects were accompanied by increases in several hypothalamic neuropeptides. Acute administration of SCH-A (30 mg/kg) prevented the decrease in energy expenditure associated with food restriction. These results indicate that MCH1 receptor antagonists may be effective in the treatment of obesity.
European Journal of Pharmacology 04/2006; 535(1-3):182-91. · 2.52 Impact Factor
-
Craig D Boyle,
Ruo Xu,
Theodros Asberom,
Samuel Chackalamannil,
John W Clader,
William J Greenlee, Henry Guzik,
Yuequing Hu,
Zhiyong Hu,
Claire M Lankin, [......],
Andrew W Stamford,
Yuguang Wang,
Jeffrey Skell,
Stanley Kurowski,
Subbarao Vemulapalli,
Jairam Palamanda,
Madhu Chintala,
Ping Wu,
Joyce Myers,
Peng Wang
[show abstract]
[hide abstract]
ABSTRACT: In search of a PDE5 inhibitor for erectile dysfunction, an SAR was developed from a PDE1/PDE5 purine series of leads, which had modest PDE5 potency and poor isozyme selectivity. A compound (41) with PDE5 inhibition and in vivo activity similar to sildenafil was discovered from this effort. In addition, purine 41 demonstrated superior overall PDE isozyme selectivity when compared to the approved PDE5 inhibitors sildenafil, vardenafil, and tadalafil, which may result in a more favorable side-effect profile.
Bioorganic & Medicinal Chemistry Letters 06/2005; 15(9):2365-9. · 2.55 Impact Factor
-
Mark D McBriar, Henry Guzik,
Ruo Xu,
Jaroslava Paruchova,
Shengjian Li,
Anandan Palani,
John W Clader,
William J Greenlee,
Brian E Hawes,
Timothy J Kowalski,
Kim O'Neill,
Brian Spar,
Blair Weig
[show abstract]
[hide abstract]
ABSTRACT: Melanin concentrating hormone (MCH) is involved in regulation of food intake and energy homeostasis. Antagonists of the MCH receptor are expected to affect food intake and weight gain, making MCH-R1 an attractive target for obesity treatment. Herein, we report the discovery of a novel, orally active series of MCH-R1 antagonists that exhibit in vivo efficacy in rodent obesity models.
Journal of Medicinal Chemistry 05/2005; 48(7):2274-7. · 5.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The four 2,2,5-regioisomer counterparts of SCH 51048 were synthesized and evaluated. As with the parent series, only the two cis isomers possessed any in vitro activity, and only the activity of the isomer with the R-configuration at the tetrahydrofuran 2-carbon was significant. The activity data suggests that oxygen at only one of the two possible ring positions benzylic to the difluorobenzene participates usefully in active site binding.
Bioorganic & Medicinal Chemistry Letters 08/2002; 12(13):1739-42. · 2.55 Impact Factor
-
Tetrahedron Letters 34(20):3267-3270. · 2.68 Impact Factor
